Design Therapeutics 8-K furnishes results release for Sept 30, 2025

Design Therapeutics, Inc. (DSGN) furnished an 8‑K announcing it issued a press release with financial results for the three and nine months ended September 30, 2025.

Rhea-AI Filing Summary

Design Therapeutics, Inc. (DSGN) furnished an 8‑K announcing it issued a press release with financial results for the three and nine months ended September 30, 2025. The press release is attached as Exhibit 99.1.

The company states this information is being furnished, not filed, under the Exchange Act and is not subject to Section 18 liabilities nor incorporated by reference into other filings. The report was signed by President and CEO Pratik Shah, Ph.D. on November 5, 2025.

8-K Event Classification

2 items: 2.02, 9.01

2 items

Item 2.02 Results of Operations and Financial Condition Financial

Disclosure of earnings results, typically an earnings press release or preliminary financials.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, or exhibit attachments filed with this report.

FAQ

What did Design Therapeutics (DSGN) disclose in this 8-K?

The company furnished a press release announcing financial results for the three and nine months ended September 30, 2025, attached as Exhibit 99.1.

Is the information in this DSGN 8-K furnished or filed?

It is explicitly furnished, not filed, and is not subject to Section 18 liabilities nor incorporated by reference.

Which exhibit contains the financial results press release for DSGN?

Exhibit 99.1 contains the press release dated November 5, 2025.

What period do the disclosed DSGN results cover?

The three and nine months ended September 30, 2025.

Who signed the DSGN report and when?

It was signed by Pratik Shah, Ph.D., President, Chief Executive Officer and Chairperson, on November 5, 2025.

What is the trading symbol and exchange for Design Therapeutics?

The common stock trades under DSGN on the Nasdaq Global Select Market.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 11/05/2025 - 04:10 PM Learn about SEC filing dates

0001807120false00018071202025-11-052025-11-05

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): November 05, 2025

Design Therapeutics, Inc.

(Exact name of Registrant as Specified in Its Charter)

Delaware			001-40288	82-3929248
(State or Other Jurisdiction of Incorporation)			(Commission File Number)	(IRS Employer Identification No.)
6005 Hidden Valley Road Suite 110
Carlsbad, California				92011
(Address of Principal Executive Offices)				(Zip Code)

Registrant’s Telephone Number, Including Area Code: (858) 293-4900

N/A

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock, $0.0001 par value per share		DSGN		Nasdaq Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☒

Item 2.02 Results of Operations and Financial Condition.

On November 5, 2025, Design Therapeutics, Inc. (the “Company”) issued a press release announcing its financial results for the three and nine months ended September 30, 2025. A copy of the press release is attached hereto as Exhibit 99.1.

The information in this Item and the exhibit attached hereto are being furnished and shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall they be deemed incorporated by reference into any filing under the Exchange Act or the Securities Act of 1933, as amended, whether filed before or after the date hereof and regardless of any general incorporation language in such filing.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

Exhibit No.		Description
99.1		Press Release of Design Therapeutics, Inc. dated November 5, 2025
104		Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

			Design Therapeutics, Inc.
Date:	November 5, 2025	By:	/s/ Pratik Shah, Ph.D.
			Pratik Shah, Ph.D. President, Chief Executive Officer and Chairperson